Today is National HIV and Aging Awareness Day (NHAAD). In 2021, there were 441,259 people aged 55 and older living with HIV, representing 41% of the U.S. population living with HIV. We must pay attention to the increasing number of people living long, full lives with HIV and their unique health and social needs, as well as the challenges of HIV prevention, testing, treatment, and care in older adults.
#IDMastodon #HIVMastodon #NHAAD #HIV #medicine #HealthEquity
Phase 3B non-inferiority RCT investigating efficacy, safety, and tolerability of switching to long-acting cabotegravir-rilpivirine versus continuing fixed-dose bictegravir-emtricitabine-tenofovir alefanamide.
Today is Zero HIV Stigma Day, highlighting a movement to raise awareness and take action against HIV stigma. HIV stigma negatively impacts everyone’s health, regardless of a person’s HIV status. Learn how you can take steps to Stop HIV Stigma: https://www.cdc.gov/stophivtogether/hiv-stigma/index.html
#ZeroHIVStigma #StopHIVStigma #IDMastodon #MedMastodon #HIVMastodon #HealthEquity
June 27th is National HIV Testing Day. There are more HIV testing options available now than ever before. Knowing your status empowers you to take steps to stay healthy, no matter the result. This National #HIVTestingDay, take the test and take the next step for your health:
https://bit.ly/42sCm39
Important Viewpoint in Lancet HIV by Valente et al on the importance of attention to health equity in roll-out of next-generation long-acting HIV PrEP. These medications have great potential to improve PrEP uptake and adherence but we MUST pay attention to health equity and address financial and structural barriers to access.
Let's End HIV as an Epidemic!
#HIVPrevention #HIV #HIVMastodon #IDMastodon #MedMastodon #BlackFedi #medicine #HealthEquity
https://www.thelancet.com/action/showPdf?pii=S2352-3018%2823%2900009-7
Pre-exposure prophylaxis (PrEP) is highly effective for prevention of HIV transmission and plays an important role in efforts to end the HIV epidemic within the next decade. However, disparities in access to PrEP might be fuelling disparities in the burden of HIV in the USA. The advent of next-generation PrEP formulations that do not involve daily regimens (eg, long-acting cabotegravir) holds potential to facilitate medication adherence, but if the roll-out of these formulations does not consider disparities in access, HIV disparities might be further widened.
Additional data from a mixed-methods study by Emory investigators exploring preferences for clinic communications regarding appointment reminders and peer outreach among people with HIV who were out of care. Findings showed a wide range of preferences and highlight the need for offering multiple options to promote re-engagement in care.
Today is National Black HIV/AIDS Awareness Day. Clinicians, let's do our part to stop HIV. PrEP protects patients from HIV, but it’s prescribed at a lower rate for Black Americans. We must address systemic social and health inequities to #StopHIVTogether. This #NBHAAD, learn more about prescribing PrEP:
https://bit.ly/3FWOq3W.
#IDMastodon #MedMastodon #HIVMastodon #BlackFedi #HealthEquity
Editorial by Dr. Chloe Orkin in Lancet HIV: Addressing inequalities still key to ending HIV/AIDS
https://doi.org/10.1016/S2352-3018(22)00376-9
#IDMastodon #MedMastodon #HealthEquity #globalhealth #HIVMastodon
Data from the CDC's Medical Monitoring Project: HIV Care Continuum outcomes among cisgender women with HIV did not show any meaningful improvement from 2015 - 2019. In fact, the percentage whose HIV had ever been classified as Stage 3 increased in 2019.
In order to end HIV as an epidemic in the U.S. we need to address this effectively. To do that, we must deal with social and structural determinants of health.
Michelle Floris-Moore
Rossana Rosa